My Treatment Approach: Risk-Benefit Assessment and Integration of Emerging Evidence in HER2-Positive Early Breast Cancer

Drs. Neil Iyengar and Kelly McCann review the phase III DESTINY-Breast11 trial, highlighting its design, patient population, and key findings demonstrating improved pathologic complete response rates with a trastuzumab deruxtecan–based neoadjuvant regimen in high-risk HER2-positive early breast cancer.